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MesenchymeMutations in the FBN1 gene, encoding the extracellular matrix protein ﬁbrillin-1, result in the dominant
connective tissue disease Marfan syndrome. Marfan syndrome has a variable phenotype, evenwithin families
carrying the same FBN1 mutation. Differences in gene expression resulting from sequence differences in the
promoter region of the FBN1 gene are likely to be involved in causing this phenotypic variability. In this report,
we present an analysis of FBN1 transcription start site (TSS) use in mouse and human tissues. We found
that transcription of FBN1 initiated primarily from a single CpG-rich promoter which was highly conserved
in mammals. It contained potential binding sites for a number of factors implicated in mesenchyme
differentiation and gene expression. The human osteosarcoma line MG63 had high levels of FBN1 mRNA and
secreted ﬁbrillin-1 protein to form extracellular matrix ﬁbres. The human embryonic kidney line HEK293 and
two breast cancer lines MCF7 and MDA-MB-231 had levels of FBN1 mRNA 1000 fold lower and produced
negligible amounts of ﬁbrillin-1 protein. Therefore MG63 appears to be the optimal cell line for examining
tissue-speciﬁc, biologically relevant promoter activity for FBN1. In reporter assays, the conserved promoter
region was more active in MG63 cells than in non-FBN1-expressing lines but additional elements outside the
proximal promoter are probably required for optimal tissue-speciﬁc expression. Understanding the regulation
of the FBN1 gene may lead to alternative therapeutic strategies for Marfan syndrome.© 2009 Elsevier Inc. All rights reserved.IntroductionFreely available large scale genome-wide information can be used
to investigate the evolution, expression and variation of human
disease genes. Marfan syndrome (OMIM 154700, OMIA 1204) is a
connective tissue disease, inherited in an autosomal dominant
fashion, with high penetrance but considerable phenotypic variability
(for example, see [1,2]). It is generally caused by mutation of the FBN1
gene, encoding the microﬁbrillar protein ﬁbrillin-1. Severely affected
individuals have overgrowth of the long bones, cardiovascular
abnormalities including aortic dilatation, ocular problems including
subluxation of the lenses and abnormalities of eye shape, reducedis of gene expression; DPE,
modiﬁed Eagle's medium;
ome; HEK, human embryonic
tial medium; OMIA, Online
endelian Inheritance in Man;
on start site.
idlothian EH25 9PS, UK. Fax:
Summers).
ll rights reserved.subcutaneous fat and muscle tissue and abnormalities of the lungs,
skin and integument [3]. Thus Marfan syndrome affects tissues of
mesenchymal origin, such as muscle, adipose and bone. Mutation
carriers within a family can present with highly variable clinical
manifestations, and genetic counselling based on discovery of a
mutation is difﬁcult because of this variability [4]. Recent studies [5–7]
are consistent with a haploinsufﬁciency model for dominance of FBN1
mutations, suggesting that in at least some cases reduction in the level
of normal ﬁbrillin-1 protein by 50% is sufﬁcient to cause the
phenotype. Alterations 5′ of the coding sequence, which could affect
gene transcription levels, have been identiﬁed in Marfan patients [8].
Levels of gene expression are heritable and can contribute to disease
[9,10] and FBN1 promoter region variability could thus contribute to
phenotypic variability within and between families [5].
Early analysis of expressed sequences in human mRNA showed
that FBN1 transcripts begin with untranslated sequence derived from
one of three alternative 5′ exons (named in order Exon B, A and C),
spliced to the ﬁrst exon with veriﬁed coding sequence (originally
named Exon M, now Exon 1) [11]. A recent study [12] showed that
conserved sequences upstream of human Exon A conferred promoter
activity in transient transfection analysis using HEK293 and HT1080
234 K.M. Summers et al. / Genomics 94 (2009) 233–240cells. Other authors [13] have speculated that the initiation of
transcription may occur upstream of the most 5′ putative exon,
Exon B. Since differences in FBN1 expression may contribute to
phenotypic variability in Marfan syndrome [5,6], it is important to
understand the initiation and regulation of transcription of this gene.
We have used extensive bioinformatic resources to survey the human
FBN1 gene and identify the major transcription start site. We analysed
FBN1 expression in a human osteosarcoma cell line, chosen because of
the high level of FBN1 expression in bone and primary osteoblast
cultures of human [14] and mouse (BioGPS FBN1 entry) and the bone
phenotype inMarfan syndrome [3]. Our studies illustrate the power of
available genomic resources in the study of transcriptional regulation,
and provide a framework for investigating the molecular basis of
phenotypic variation in Marfan syndrome patients.
Results
Structure of the FBN1 promoter region
The FANTOM (Functional Annotation of the Mammalian Genome)
project is an international collaborative effort to map transcriptional
start sites (TSS) of mouse and human, sponsored by the RIKEN Omics
Institute in Japan. Using CAGE (cap analysis of gene expression), a
form of genome-wide 5′-RACE analysis which detects the initial bases
of a transcript, FANTOM3 identiﬁed over 11 million transcripts in
mouse (over 7 million mapped to unique sites in the genome) and
nearly 6 million in human (more than 3 million mapped) [15]. We
used this resource to ﬁnd the TSSs of the human and mouse FBN1
genes. For mouse, a total of 788 CAGE tags (comprising the ﬁrst 20
bases of transcripts) mapped across the Fbn1 gene (Supplementary
Fig. 1A). For human, 966 tags were detected across the region of FBN1Fig. 1. Transcription start sites of mouse and human FBN1 genes, detected by CAGE analysis
Viewer as at March 2009 and show distribution of transcription start sites for mouse (upper
the base pair position on the physical map of the chromosome for mouse (mm5) and human
shown by boxes. In line (ii) arrows show the location and placement of TSS clusters. Numbers
region covered by overlapping tags in the cluster. The direction of the arrow shows the direct
Line (iii) shows validated transcripts. Boxes indicate exons and lines indicate sequences whic
mouse and human FBN1 genes are shown in Supplementary Fig. 1.(Supplementary Fig. 1B). There were clusters of CAGE tags indicating
TSSs in the forward orientation over nearly 1 kb encompassing Exons
A, B and C in both human (719 tags) and mouse (612 tags) (Fig. 1).
Many of these tags were singletons that did not overlap with each
other to form a cluster.
Against a background of low-level initiation across the region (as
shown in Fig. 1 and Supplementary Fig. 1A), there were two start site
clusters 5′ of Exon 1 in mouse (Fig. 1). One, with 484 CAGE tags,
corresponded with Exon A. The other start site cluster, with 85 tags,
was located closer to Exon 1 and corresponded with the published
Exon C of human (Fig. 1). In addition 4 tags were close to the position
of Exon B of human (Fig. 1). These results indicate that the promoter
initiating at Exon A was most commonly used in the tissue types
examined in mouse. The CAGE results also provided information on
cell types which express FBN1 mRNA. In mouse, the majority of
detected transcripts (440 of 484 for Exon A and 45 of 85 for Exon C)
came from embryo mRNA. Mouse RNA also showed two additional
start sites (with 18 and 12 tags respectively) in the reverse direction in
the second intron (shown in Supplementary Fig. 1A). The sites were in
highly conserved sequences.
For human, there was a single major TSS cluster, corresponding
with Exon A. 373 of the 658 transcripts were found in mRNA prepared
from skin cells and 177 were from adipose tissue. There was no focus
of TSS in the region of either Exon B or Exon C, with additional TSS
clusters of one to 13 tags scattered over the whole region from Exon B
to Exon 1 (Fig. 1). This indicates that, for the tissues and cell types
sampled, there was no selective use of Exons B and C in humans. The
reverse TSSs of the mouse second intron were not seen in the human
RNA but there was a cluster of 19 forward tags at the beginning of
coding Exon 8 (Supplementary Fig. 1B). The differences between
human and mouse may be attributable to the different tissues. The diagrams are redrawn from those generated by the FANTOM3 Genome Elements
) and human (lower) FBN1 genes 5′ of the putative start codon in Exon 1. Line (i) shows
(hg17). The positions of putative Exons A, B and C and the ﬁrst coding exon, Exon 1, are
indicate the number of TSSs found at that location and the length of the arrow shows the
ion of transcription. Gray arrows show low frequency tags (less than 1 in 105 total tags).
h are spliced out. Line (iv) shows the regions of CpG islands. TSSs covering the complete
Fig. 2. Histograms of mouse and human TSS usage. Mouse and human sequences were
aligned and the number of tags starting on each base was graphed. Y axis indicates
number of transcripts starting on that base. Bracket shows the pyrimidine region. Small
boxes shows the putative Inr (solid) and DPE (dotted) of Guo et al. [12]. Large box
indicates the region expanded below, showing the ﬁrst base of the transcripts. Main
sequence covers bases −1046 to −856 in the human sequence, numbered from the
ATG start codon (at position 5348 in GenBank entry L19896).
235K.M. Summers et al. / Genomics 94 (2009) 233–240sampled in the CAGE analysis, or may reﬂect a species-speciﬁc
difference in regulation of FBN1.
We analysed the nucleotides at which the transcripts initiated for
human and mouse (Fig. 2). The large majority conformed to a Py Pu
initiator consensus, with CA the most common dinucleotide (A being
the ﬁrst base of the transcript). Although Exon A transcripts initiated
over a wide region, in human the majority initiated at one of three
sites, while in mouse there was a dominant TSS with a second alsoTable 1
Transcription factor binding motifs identiﬁed in the conserved FBN1 promoter region.
Motif sequence Locationa Transcription factor families
GTGGAAAG −1107 to −1114 C/EBP
TGTCATTT −1051 to −1044 POU-domain factors
TTTTCTTTTTCTTTCTTTTTTT −1046 to −1025 Broad complex, paired homeobox,
forkhead and HMG-IY families
TTTTTTTAAAAAAA −1031 to −1018 MEF2, homeobox factors e.g. PRX family
AAGTAT −1010 to −1005 GATA
ATACTT −969 to −964 GATA
TTTCTC −1004 to −999 E2F
GAGAAA −994 to −989 E2F
TGTGG −918 to −914 RUNX
CCACA −909 to −905 RUNX
CCACA −893 to −889 RUNX
CAGCTG −890 to −885 MYO-D, MYOGENIN, SNAIL
CAGCTG −881 to −876 MYO-D, MYOGENIN, SNAIL
a Location in the human sequence; bases 5′ of the ATG start codon at position 5348 in Gshowing increased starts. The alignment of the CAGE tags on the
sequence of human and mouse (Fig. 2) revealed that base changes
between species were correlated with differences in the frequency of
starting at particular bases. A GC-rich element likely to bind the
transcription factor SP1 started 40 bases upstream of the ﬁrst major
TSS in both species. A series of GC-rich elements conforming to the
variant GCG trinucleotide repeat downstream promoter element
identiﬁed previously by genome-wide promoter analysis [16] was
found 3′ of themajor TSSs (shown in Supplementary Fig. 2). Therewas
an apparent deletion in rodents bringing the GCG echo closer to the
start site (Supplementary Fig. 2). The region of the TSSs of FBN1
conformed to the deﬁnition of a CpG island (lines labelled iv in Fig. 1)
[17].
Analysis of conserved FBN1 sequence
Sequence conservation of the region around the Exon A TSS was
examined in 28 mammalian species for which adequate sequence
information was available in the Ensembl data base and trace server
(species listed in Supplementary Fig. 2). Transcription factor binding
motifs were detected using rVista (TRANSFAC motif library) and
compared with analysis using the JASPAR motif library (see Materials
and methods). Table 1 shows conserved sites in the region of the TSSs
and Supplementary Fig. 2 shows the same sites across all species
tested. A highly conserved element (TTTCTCGCGAGAAA), containing
the palindrome reported previously [12], was identiﬁed to contain an
inverted repeat dual binding motif for the transcription factor E2F
[18,19]. Across 28 mammals, the putative E2F binding sites only varied
by deletion of the terminal T and A in Echinops telfairi and addition of a
CA dinucleotide inMyotis lucifugus (Supplementary Fig. 2). Because of
the repeat nature of the sequences, and the fact that these sequences
were derived from the trace database and are not fully validated, these
could be sequencing errors, but may represent true variation. Inverted
repeats of a core sequence AAGTAT (Table 1 and Supplementary Fig. 2)
were also conserved. These sites were candidate GATA motifs. Two
conserved E-boxes (CAGCTG) were detected (Table 1 and Supple-
mentary Fig. 2) with a third site further downstream in mouse and rat
only. Three conserved E-boxes were also found in the Exon C promoter
region (not shown). As indicated in Supplementary Fig. 2, 3′ of the
main initiator region there were three conserved binding motifs for
members of the RUNX transcription factor family (TGTGG) [20].
Immediately upstream of the major TSS region was a stretch of
pyrimidines (length ranging from 21 in Oryctolagus cuniculus to 39 in
Spermophilus tridecemlineatus) ﬂanked by a string of As at the 3′ end
and a G-rich region at the 5′ end (Supplementary Fig. 2). The 5′ end of
the G-rich region contained a conserved octamer-like motif
(TGTCATTT) which could potentially bind POU-domain factorsTissue/function Reference
Cell cycle, differentiation in multiple lineages,
activation of RUNX2 (CEBPD)
[35,36]
General transcription factor, mesenchymal stem cell
lineage determination (OCT4)
[37,38]
Mesenchyme and other lineages, myogenesis (PAX3/7) [39]
Muscle development Mesenchyme differentiation [40,41]
Mesenchymal lineage determination (GATA4) [42,43]
Mesenchymal lineage determination (GATA4) [42,43]
Proliferating cells; inhibition of chondrocyte differentiation (E2F1) [18,19,44,45]
Proliferating cells; inhibition of chondrocyte differentiation (E2F1) [18,19,44,45]
Skeletal development (RUNX2) [20,46]
Skeletal development (RUNX2) [20,46]
Skeletal development (RUNX2) [20,46]
Muscle development [47,48]
Muscle development [47,48]
enBank entry L19896.
Table 2
FBN1 mRNA expression levels in cell lines.
Cell line Expression relative to HPRT (SD)
Experiment 1 Experiment 2 Experiment 3
MG63 14.07 (4.67) 65.34 (5.01) 21.86 (5.36)
MDA-MB-231 0.21 (0.03) 0.20 (0.03) NA
MCF7 NA 0.20 (0.03) 0.21 (0.01)
HEK293 0.01 (0.0006) 0.06 (0.01) 0.01 (0.001)
Results for representative experiments are shown. For each, cDNA synthesis and
quantitative PCR were carried out at the same time for duplicate RNA samples, each
assayed in triplicate. NA — not assayed in the experiment.
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(Supplementary Fig. 2). The 3′ string of Ts followed by a string of As
was predicted to be a binding site for the myogenic enhancer-2 (MEF-
2) family. The AT-rich sequence also contained predicted binding
motifs for a range of homeobox factors. The conserved pyrimidine
string ﬂanked by purines was not found in the 5′ regions of other
members of the ﬁbrillin/LTBP family or other genes. There were a
number of potential transcription factor binding motifs within this
sequence, including motifs for the broad complex, paired homeobox,
forkhead and HMG-IY families. In addition, analysis using the RECON
programme [21] suggested that the pyrimidine-rich sequence was
likely to have a role in nucleosome phasing (data not shown).
Despite the remarkable conservation of the promoter region in
mammals (also noted in other reports [11–13] using a more limited
range of species), there were no matches to the Exon A sequence orFig. 3. Immunocytochemical staining of cell lines for ﬁbrillin-1. All cells were stained at day 1
antibody; right hand panels show staining using an isotype antibody control (see Material
MG63; (B) HEK293. Original magniﬁcation 60×.the TSS region found by BLAT or BLAST analysis in completed or draft
genomes of any other vertebrate species, including birds (chicken and
zebra ﬁnch), ﬁsh (fugu, zebraﬁsh, medaka, stickleback, pufferﬁsh), a
reptile (anole lizard) and an amphibian (Xenopus tropicalis), nor in the
platypus or the wallaby Macropus eugeneii. Many of these species do
have annotated FBN1 genes, although the initial exons are frequently
missing. For example, the ﬁrst exon annotated for chicken corresponds
with the second coding exon of human and the ﬁrst for platypus with
the sixth coding exon. The absence of this sequence in somemammals
and in other vertebratesmay thus be due to incomplete sequencing, or
may reﬂect the evolutionary relationship of the Australian fauna to
non-mammalian vertebrates.
As can be seen in Supplementary Fig. 2, sequence homology across
species degenerates 3′ of the strong Exon A splice donor (CCA/GT)
that is conserved across species and around 300 bp upstream of the
pyrimidine stretch, before Exon B. BLAT and BLAST analysis of the
previously identiﬁed human Exon B (∼300–400 bp upstream of Exon
A) and Exon C (∼300–400 bp downstream of Exon A) found no
signiﬁcant matches in the mouse genome.
FBN1 mRNA and protein expression in cultured cells
Analysis of public microarray data (see Materials and methods)
showed that FBN1 was strongly expressed in human adipocytes,
smooth muscle, placenta, cardiac myocytes and some fetal tissues.
From the microarray results, expression was low in most cell lines,
other than those of mesenchymal origin. In the mouse, Fbn14 after plating. Left hand panels show staining using a mouse monoclonal anti-ﬁbrillin-1
s and methods). Images are representative of at least three separate experiments. (A)
Fig. 4. Luciferase activity for different cell lines and promoter constructs. Y axis shows luciferase activity relative to the empty vector pGL2B. Results show average of ﬁve (HEK293),
four (MG63, MCF7), or two (MDA-MB-231) separate experiments. Bars show standard error. Values for pGL2C (SV40 promoter control) were 1990±1219 (MG63); 25±10
(HEK293); 1238±370 (MCF7) and 446±156 (MDA-MB-231). Horizontal lines below show the relationship of the FBN1 sequence contained in each construct, comparedwith the P1
and P2 constructs used previously [12].
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conﬁrm the level of expression of human FBN1 in the cell lines used in
the present study, we surveyed mRNA levels using quantitative
reverse transcriptase PCR. As shown in Table 2, the highest expression
was seen in the human osteosarcoma line MG63 where expression
relative to HPRT ranged from 14 to 65 in different experiments. MG63
cells showed more than 1000-fold greater expression than HEK293
cells (expression relative to HPRT between 0.01 and 0.06). The human
breast cancer cell lines MDA-MB-231 and MCF7 also expressed much
lower FBN1mRNA levels thanMG63 cells (expression relative to HPRT
approximately 0.20; Table 2).
Since there was detectable FBN1mRNA expression in all cell types
tested, we also assessed the production of ﬁbrillin-1 protein in these
cell lines using immunocytochemistry with a mouse anti-ﬁbrillin-1
monoclonal antibody [22]. As shown in Fig. 3A, at day 14 after plating
the majority of the staining in MG63 cultures was present in the
extracellular region, in ﬁbres similar to those seen in skin and aortic
ﬁbroblast cultures (for example, see [2,22–24]). In contrast, at 14 days
after plating HEK293 cells showed minimal staining, with no ﬁbres
(Fig. 3B). This suggests that themRNA expression seen in HEK293 cells
(Table 2) does not result in production of ﬁbrillin-1 protein that is
incorporated into the extracellular matrix. The human breast cancer
cell linesMCF7 andMDA-MB-231 (not shown), showed similar results
to HEK293, consistent with quantitative reverse transcriptase PCR
results (Table 2).
Assessment of human FBN1 promoter activity
Our bioinformatic study (based on CAGE analysis and sequence
conservation) identiﬁed the TSS regionwhich should be preceded by a
promoter. The experimental study showed that the cell line MG63
expressed FBN1 mRNA and produced a matrix containing ﬁbrillin-1,
while the three other cell lines (including the line HEK293 used in
the previous study [12]) had low levels of mRNA and protein. We
therefore wished to determine whether the putative promoter region
had lineage-speciﬁc promoter activity. A 662 bp sequence including
the full conserved TSS region of the human FBN1 gene (as identiﬁed
by CAGE analysis) was ampliﬁed by PCR and inserted into the ﬁreﬂyluciferase expression vector pGL2B, upstream of the luciferase coding
sequence. This construct covered bases −1351 to −690 numbered
from the putative start codon (based on GenBank entry L19896). It
therefore included the experimentally-veriﬁed major TSS cluster. As
shown in Fig. 4, this promoter construct (pUQ42) had detectable
promoter activity in all of the human cell lines studied. Expressed
relative to the pGL2B basal activity, the promoter activity of pUQ42
was 5–10 fold greater in MG63 cells than HEK293 cells or the human
breast cancer lines (Fig. 4), These data are consistent with the higher
level of mRNA expression in MG63 cells (Table 2). Deletion of 104
bases from the 5′ end (pUQ12) made little difference to the activity in
most cell lines, but deletion of 236 bases from the 5′ end (pUQ09)
reduced the activity considerably in MG63, HEK and MCF7 cells
(Fig. 4). A construct with an internal deletion of one of the two
putative E2F sites also showed reduced activity in most experiments
for all cell lines (Fig. 4). When expressed relative to the activity of a
positive control, the SV40-based pGL2C (Fig. 4 legend), FBN1 promoter
activity of pUQ42 was three times higher in MG63 than in the breast
cancer lines but this comparison could not be made for HEK293 cells
because activity of the positive control was very low.
Discussion
This study used publicly available genomic resources to assess the
promoter region of FBN1, the genewhich is associatedwith the human
genetic disease Marfan syndrome. The analysis of TSS use for both
mouse and human supported the view that the FBN1 gene has a single
dominant promoter, and hence that Exon A is the dominant 5′-non-
coding exon of the gene. For humans, transcripts containing Exon B or
C probably derive from the background low-level TSSs scattered over
the 5′ region (Fig. 1), with transcripts containing weak splice donors
that enable splicing into the strong splice acceptor upstream of Exon 1.
Indeed, sequences ﬂanking putative Exon B had minimal promoter
activity in reporter assays [12]. There are also likely to be additional
alternative 5′ exons. For example, a number of singleton TSSs were
detected by CAGE analysis. Singletons usually represent real TSSs [25],
so greater depth of sampling would probably validate these sites in
FBN1 and identify others. There is a similar complex pattern of
238 K.M. Summers et al. / Genomics 94 (2009) 233–240alternative exons in the trophoblast-speciﬁc promoter region of the
Csf1r locus in mouse [26].
The results identiﬁed the FBN1 promoter as a broad class promoter,
with a number of closely located TSS rather than a distinct TSS at a
single position [27]. As seen here, broad class promoters commonly
correspond to CpG islands. Genomewide analysis [16] has shown that
the dominant TSSs within a broad promoter are preceded by a GC-rich
element that binds SP1, around 40–50 bp upstream. Our study
identiﬁed this element in the FBN1 promoter, highly conserved across
mammalian species (Supplementary Fig. 2). Around 20 bp down-
stream of the major TSS of a broad promoter, genome analysis has
identiﬁed another GC-rich element, with a characteristic GCG
trinucleotide core [16], echoed by a third element about 10 bp further
downstream. This structure was also found in the FBN1 promoter
region (Supplementary Fig. 2). The placement of these GCG elements
might explain the preferential use of alternative TSS between the
species.
In mouse, Fbn1 is expressed at high levels in proliferating
mesenchymal cells and tissues, regardless of their lineage commit-
ment (smooth, cardiac and skeletal muscle, adipocytes, endothelial
cells, osteoblasts, ﬁbroblasts and chondrocytes) and absent from
haemopoietic cells (see BioGPS). We therefore re-examined the
promoter region for candidate conserved sequence elements that
might explain this pattern of expression and detected a number of
relevant transcription factor binding motifs (Table 1). We then
scanned the literature to identify transcription factors that have
been shown to bind these motifs and have also been implicated in
mesenchyme lineage determination (references in Table 1). The
survey of transcription factor binding sites in a previous report [12]
did not take account of the pattern of expression of FBN1. For example,
a binding motif for AP-2 was highlighted, but this is unlikely to be
functional since the AP-2 family is associated with gene regulation in
ectoderm and neural crest lineages [28] where FBN1 is not expressed.
The previous study highlighted a motif for the NFI family of factors
which has been implicated in development of the nervous system.
This motif may be relevant, since one member, Nﬁx, is largely co-
expressed with Fbn1 in mouse mRNA (BioGPS database and Summers
et al., in preparation) and the mouse knockout had skeletal and
muscle abnormalities as well as neurological effects [29]. Amongst the
candidates we identiﬁed, the predicted GATA motifs were previously
shown to be essential for promoter activity in HEK293 cells [12].
Further work is required to assess whether all the detected motifs
are active.
The previous study of the FBN1 promoter region [12] did not
identify the TSSs experimentally. We found no TSSs detected by
CAGE analysis at the Inr they proposed from sequence analysis [12]
(see Fig. 2) and TSS distribution suggested that the major Inr is
downstream of that site. Our analysis of TSSs for FBN1, also revealed
that the active promoter constructs in the previous study [12] lacked
key elements of the promoter region. As shown in the diagram in
Fig. 4, construct P1, the most active construct of that study, did not
contain the major TSS region identiﬁed by CAGE. Construct P2, with
approximately half the activity of P1, contained the TSS region but
lacked most of the 5′ sequence which is likely to be necessary for full
promoter activity. The most active construct used in our study
contained both the TSS region and the 5′ sequence of P1 (Fig. 4). In
addition, as demonstrated by our results, the previous study [12]
examined promoter activity in a cell line, HEK293, that makes little
FBN1 mRNA (Table 2) and does not make a ﬁbrillin-1 matrix (Fig.
3). The level of FBN1 mRNA in MG63 cells was at least 1000 times
greater than in HEK293 cells (Table 2). This difference is consistent
with expression in corresponding primary cells. MG63 is an
osteosarcoma and FBN1 mRNA level is high in primary osteoblasts
and bone [14]. Conversely, HEK293 is probably neuronal [30], and the
FBN1 gene is not expressed in neuronal tissues or primary cells (data
from BioGPS and RefExA).Despite the massive differential expression of FBN1 mRNA,
promoter activity for the highly conserved proximal promoter region
in MG63 cells was only ∼5-fold higher than in the two breast cancer
lines, relative to either the pGL2B empty vector, or the pGL2C SV40
positive control (Fig. 4). In HEK293 cells, the SV40 promoter was less
active than the FBN1 promoter. HEK cells were created by transforma-
tion with adenovirus, and the adenoviral E1A gene product represses
transcription from a number of promoters including SV40 [28],
accounting for the low level of luciferase activity in HEK cells
transfected with pGL2C. The E1A product expressed in HEK293 cells
could act in part through the E2F motif of the FBN1 promoter, a well-
documented target of E1A [29]. Given the presence of an E2F site, the
dependence of activity on that site (Fig. 4 and [12]), and the fact that
extracellular matrix production is itself associated with cell prolifera-
tion, the activity of the promoter in FBN1-expressing as well as non-
expressing cells may be controlled by the cell cycle. Distal elements
upstream and downstream of the conserved promoter may contribute
to tissue speciﬁcity. The ECR Browser revealed additional regions of
substantial homology upstream of the Exon A promoter. MG63 cells
will be an appropriate cellular system in which to determine the role
of these elements in expression of FBN1.
Variations in promoter activity can have a heritable effect on gene
expression [9,10]. Thus polymorphic variation in the critical elements
of the FBN1 promoter may be involved in controlling the absolute
level of FBN1 mRNA and hence protein. Once these elements and the
transcription factors which bind to them have been determined,
studies in patient and control cells will be required to assess the
signiﬁcance in determining the severity and variability of the
phenotype in Marfan syndrome.
Materials and methods
Bioinformatic analysis of the FBN1 promoter region in mammals
Microarray data in the public domain (BioGPS, RefExA, GeoPro-
ﬁles) were searched to establish cell types with high and low
expression levels of FBN1 mRNA. The human and mouse FBN1
transcriptional start sites (TSS) were identiﬁed from the FANTOM3
CAGE database [15,25,30]. FBN1 homologues in 28 mammalian
genomes were retrieved from the Ensembl trace sequence database,
using the program SSAHA to identify matches with the 100 bp region
containing the TSS and 100 bases ﬂanking it on both sides. Macropus
eugenii sequences were from The Wallaby Genome Project database.
Multiple alignments were performed using ClustalW2 [31] and
corrected manually using the alignment editor associated with the
program.
An analysis of evolutionarily conserved sites in the promoter
region was made with the ECR Browser (comparing mouse, human,
rhesus macaque and dog genomes). The program rVISTA 2.0 was then
used to identify transcription factor binding motifs within the
conserved regions (based on TRANSFAC Professional V10.2 library
[32]) and these results were correlated with those derived using the
JASPAR database [33]. Nucleosome phasing prediction for the
conserved region was made using the RECON program [21].
Cells and cell culture
HumanMG63 osteosarcoma cells and humanMCF7 and MDA-MB-
231 breast cancer cells were grown in minimal essential medium
(MEM) with 10% heat inactivated fetal calf serum, 2 mM L-glutamine
(Glutamax-1), 100 μg/mL streptomycin sulphate and 100 U/mL
penicillin. MG63 and MCF7 cells were supplemented with 0.1 mM
non-essential amino acids and 1.0 mM sodium pyruvate. MCF7 cells
were also supplemented with 10 μg/mL bovine insulin (Sigma-
Aldrich, Castle Hill, NSW, Australia). Human embryonic kidney cells
(HEK-293) were grown in Dulbecco's modiﬁed Eagle's medium
239K.M. Summers et al. / Genomics 94 (2009) 233–240(DMEM) in the presence of fetal calf serum, L-glutamine, penicillin
and streptomycin as above. Media components were from Invitrogen
Australia, Mt Waverly, Victoria, Australia, except where speciﬁed. The
cells were maintained in a humidiﬁed incubator at 37 °C with 5% CO2.
FBN1 mRNA and protein expression analysis
RNA was harvested from cells that were conﬂuent at the time of
harvest, 7 days after seeding into T75 ﬂasks, using the RNeasy Mini Kit
(Qiagen Inc, Hilden, Germany). cDNA was synthesised in duplicate
using oligo-dT primers (Geneworks, Adelaide, South Australia,
Australia) and Superscript reverse transcriptase (Invitrogen Austra-
lia). Quantitative real time PCR was performed in triplicate for each
cDNA using SYBRGreen PCR mastermix (Applied Biosystems, Scor-
esby, Victoria, Australia) in an ABI Prism 7000 Sequence Detection
System (Applied Biosystems) according to the manufacturer's
instructions. Expression was calculated relative to hypoxanthine
guanine phosphoribosyl transferase. Primer sequences are available
in Supplementary Table 1. Fibrillin-1 protein was detected using a
monoclonal antibody by immunocytochemistry as described pre-
viously [22].
FBN1 promoter analysis
Primers were designed using the program Primer3 to amplify the
region identiﬁed to contain the major TSS for human FBN1. Eight
nucleotides containing the recognition site for the restriction enzyme
BglII were added to the primers at the 5′ end. Primer sequences for all
constructs and their location relative to the putative ATG start codon
are available in Supplementary Table 1. PCR fragments were cloned
into the T-tailed vector pGEM T-easy (Promega Corp, Madison, WI,
USA). Fragments were excised from the vector using BglII and ligated
into the phosphatase treated BglII site of the luciferase reporter vector
pGL2B (Promega). Deletion of 8 bases within the putative promoter
region was accomplished using a site directed mutagenesis protocol
[34].
Plasmids were prepared using an endotoxin-free maxiprep kit
(Qiagen). Twenty-four hours prior to transfection, a total of 105 cells
were plated into wells of a 12 well plate. Antibiotics were removed
from the medium three hours prior to transfection. Prior to
transfection, the medium was replaced with Opti-MEM (antibiotic
and serum free). 400 ng of the pGL2B construct was transfected using
LipofectAMINE 2000™ (Invitrogen Australia) following the manufac-
turer's instructions. Four hours after adding the transfection mix,
mediumwas replaced with DMEM containing 10% fetal calf serum and
appropriate supplements. Twenty-four hours after transfection, the
cells were washed with phosphate buffered saline, lysed with 120 μL
lysis buffer (0.5 M HEPES at pH 7.9, 1 mM MgCl2, 1 mM CaCl2, 0.1%
triton N-101) and frozen at −80 °C. The activity of luciferase was
measured in 50 μL of lysate using the Luciferase Reporter Gene Assay
High Sensitivity (Roche Applied Science, Castle Hill, NSW, Australia) in
a 1450 Microbeta TriLux luminometer (PerkinElmer, Fremont, CA,
USA). Luciferase activity was corrected for protein concentration
assayed using the Bradford reagent (BioRad Laboratories, Gladesville,
NSW, Australia). All experiments were performed in triplicate.
Web sources
BioGPS The Gene Portal Hub, http://biogps.gnf.org
BioGPS FBN1 entry, http://biogps.gnf.org/#goto=genereport&id=2200
ClustalW2, http://www.ebi.ac.uk/Tools/clustalw2/index.html
ECR Browser, http://ecrbrowser.dcode.org/
Ensembl Database, http://www.ensembl.org
Ensembl Trace Sequence Database, http://trace.ensembl.org/
FANTOM3 CAGE Database, http://fantom.gsc.riken.jp/3/GenBank, http://www.ncbi.nlm.nih.gov/sites/entrez?db=nucleotide
GeoProﬁles, Gene Expression Omnibus, http://www.ncbi.nlm.nih.
gov/geo/
JASPAR Transcription Factor Motif Database, http://jaspar.cgb.ki.se/
Primer3 primer design program, http://frodo.wi.mit.edu/
RefExA, Laboratory for Systems Biology and Medicine, http://
www.lsbm.org
RECON, http://wwwmgs.bionet.nsc.ru/mgs/programs/recon/
rVISTA, http://rvista.dcode.org/
Wallaby Genome Project, http://www.hgsc.bcm.tmc.edu/project-
species-m-Wallaby.hgsc?pageLocation=Wallaby
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